Introduction {#Sec1}
============

Recent publications of data extracts from population registries have triggered debate about a potential relationship between treatment with insulin glargine (A21Gly,B31Arg,B32Arg human insulin) and an increased incidence of cancer or breast cancer \[[@CR1]--[@CR4]\]. Here, we fulfil an obligation to report the evidence from randomised clinical trials (RCTs) within the manufacturer's database.

All RCTs sponsored by sanofi-aventis that compared the use of insulin glargine with another active comparator in either type 1 or type 2 diabetes and had a treatment duration of at least 4 weeks were included in this analysis. These studies included people with either type 1 or type 2 diabetes, and were either part of the initial development plan for the registration of the product (Phase 2 and 3) or conducted after the commercial launch of insulin glargine (Phase 4 studies).

Methods {#Sec2}
=======

As it is obligatory for all sponsored trials routinely to report serious adverse events to the manufacturer, and as the manufacturer has a database of such studies, no literature search was performed. Only RCTs that compared insulin glargine with an active comparator and that had a final clinical study report available for review on 15 May 2009 were included in this analysis.

**Studies and ascertainment of malignancy** A thorough review of the sanofi-aventis safety database for the identified studies was performed to assess the incidence of any malignancies that led to reports of serious adverse events during the conduct of the trials. All RCTs of insulin glargine were included. All serious adverse events coded in the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class of neoplasms---benign, malignant and unspecified---were included in the evaluation \[[@CR5]\]. An adverse event is classified as serious if it fulfils the criteria set down by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), that is if it: is life-threatening or results in death; requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is another 'medically important' event that may jeopardise the study participant or may require intervention to prevent one of the other outcomes listed in the definition above \[[@CR6]\]. The ICH recommends that cancers are characterised as 'medically important' adverse events and, therefore, are classified as serious adverse events \[[@CR6]\].All such identified records in the sanofi-aventis pharmacovigilance database were reviewed, by treatment, by the manufacturer's drug safety personnel with experience of adverse event reporting, and only treatment-emergent neoplasms judged to be malignant were included, independent of treatment group. Each person was counted only once, although separate counts for people and cases are provided if more than one malignancy was reported in the same person. Relative risks and 95% confidence intervals were calculated for insulin glargine relative to the comparator for the total incidence of malignancies and for individual classifications using all identified RCTs in type 1 and type 2 diabetes combined.

Results {#Sec3}
=======

The Clintrace sanofi-aventis safety database contains 31 eligible studies. Twelve studies were performed in people with type 1 diabetes and 19 studies in people with type 2 diabetes; most of the studies compared insulin glargine with NPH insulin (20 studies). Nearly all (29) were parallel-group trials (two had a crossover design). Details of these studies are summarised in Table [1](#Tab1){ref-type="table"}. Most studies were open label, 19 were of around 6 months in duration, with six of longer duration, notably the retinopathy study 4016, which had a duration of 5 years \[[@CR7]\]. Table 1Details of the studies included in the analysisTrial number (reference)ComparatorStudy duration (weeks)Participants randomised and treated (insulin glargine/control arm)Type 1 diabetes 2002 \[[@CR15]\]NPH4168/88 2003 \[[@CR16]\]NPH4223/110 3001 \[[@CR17]\]NPH28292/293 3003 \[[@CR18]\]NPH28174/175 3004 \[[@CR19]\]NPH28264/270 3005 \[[@CR20]\]NPH16310/309 4003^a^Ultralente6--729/27 4005 \[[@CR21]\]NPH3226/25 4006 \[[@CR22]\]NPH3253/52 4010 \[[@CR23]\]NPH3062/63 4030 \[[@CR24]\]NPH or lente2485/90 4036 \[[@CR25]\]Insulin lispro as CSII2426/24Type 2 diabetes 2004 \[[@CR26]\]NPH4136/68 2006^a^ 'Conventional insulin'457/57 3002 \[[@CR27]\]NPH52289/281 3006 \[[@CR28]\]NPH28259/259 3102^a^NPH28158/159 3502 \[[@CR29]\]OGLDs24203/197 4001 \[[@CR30]\]NPH28464/233 4002 \[[@CR31]\]NPH24367/389 4012 \[[@CR32]\]NPH24221/223 4013 \[[@CR33]\]NPH28231/250 4014 \[[@CR34]\]Rosiglitazone24105/112 4016 \[[@CR7], [@CR8]\]NPH5 years514/503 4020^a^Pioglitazone48164/181 4021^a^Insulin lispro 25%, insulin lispro protamine 75%, mix24113/99 4022^a^OGLDs48118/130 4027 \[[@CR35]\]NPH 30/7028177/187 4040 \[[@CR36]\]Insulin lispro44205/212 4042 \[[@CR37]\]OGLDs and dietary measures40103/108 6001 \[[@CR38]\]NPH3661/49^a^Data available from sanofi-aventis on requestCSII, continuous subcutaneous insulin infusion (of insulin lispro \[B28Lys,B29Pro human insulin\]); OGLDs, oral glucose-lowering drugs

Overall, 10,880 people were included in the analysis, with 5,657 people randomised to insulin glargine and 5,223 people randomised to the comparator, representing a total follow-up time of 4,711 and 4,524 person-years, respectively. Baseline characteristics of the participants were comparable between treatment groups (Table [2](#Tab2){ref-type="table"}). Table 2Participant characteristics in the studies identified for inclusion in the analysisTrial numberAge (years)Sex ratio M/FBMI (kg/m^2^)Duration of diabetes (years)Baseline HbA~1c~ (%)Insulin glargineComparatorInsulin glargineComparatorInsulin glargineComparatorInsulin glargineComparatorInsulin glargineComparatorType 1 diabetes 2002^a^37.337.951.2/48.853.4/46.624.224.516.316.37.97.9 2003^a^36.635.760.5/39.561.8/38.224.024.09.511.08.07.8 300139.4 (12.8)39.0 (11.7)54.8/45.256.7/43.324.6 (3.2)25.1 (3.3)15.9 (11.5)15.2 (9.4)7.9 (1.2)8.0 (1.2) 300311.8 (2.5)11.5 (2.4)55.7/44.348.0/52.018.8 (2.8)18.9 (2.9)5.0 (3.0)4.7 (3.1)8.5 (1.3)8.9 (1.6) 300438.2 (12.2)38.9 (11.9)53.4/46.647.8/52.225.6 (4.0)25.9 (4.6)17.9 (11.7)16.9 (10.0)7.7 (1.2)7.7 (1.1) 300538.9 (12.2)39.5 (12.2)48.7/51.352.4/ 47.625.5 (3.4)25.7 (3.9)18.7 (11.5)18.4 (11.8)7.6 (1.2)7.7 (1.2) 400336.4 (9.2)37.4 (9.2)45.0/55.026.0/74.026.3 (3.5)25.2 (3.1)N/AN/AN/AN/A 400515.1 (1.7)14.5 (1.6)46.2/53.838.5/61.523.3 (4.1)23.0 (3.8)6.1 (3.6)8.0 (3.3)9.4 (1.1)9.1 (1.4) 400641.1 (13.9)41.1 (10.7)32.0/68.041.4/58.626.5 (2.8)25.4 (3.0)22.4 (15.1)20.8 (11.3)8.1 (0.8)7.9 (0.8) 401041.7 (12.9)39.3 (13.9)38.7/61.339.7/60.327.0 (3.6)26.0 (3.9)17.9 (10.5)17.1 (9.7)9.2 (1.1)9.7 (1.3) 403013.1 (2.4)13.3 (2.5)45.9/54.145.6/54.422.7 (3.8)22.7 (5.0)5.1 (3.4)5.4 (3.7)7.8 (0.8)8.0 (0.8) 403642.4 (9.9) 37.6 (12.3) 53.8/46.2 54.2/45.8 24.3 (1.9) 23.8 (2.7) 20.9 (10.6) 18.5 (8.4) 7.8 (0.6) 7.7 (0.7)Type 2 diabetes 200660.9 (10.8)60.5 (9.8)59.6/40.459.6/40.427.0 (2.9)26.3 (3.3)13.4 (8.2)13.8 (8.6)9.3 (1.1)9.6 (1.2) 2004^a^59.559.261/3957.4/42.627.227.79.79.19.7 (1.3)9.5 (1.4) 300259.6 (9.3)59.4 (9.1)53.3/46.754.1/45.929.3 (4.3)28.8 (4.3)10.2 (6.2)10.5 (6.0)9.0 (1.2)8.9 (1.1) 300659.5 (9.7)59.2 (9.9)57.9/42.162.2/37.830.7 (5.0)30.4 (5.1)13.4 (8.3)14.1 (9.0)8.6 (1.2)8.5 (1.2) 3102^b^----------------9.1 (1.1)9.1 (1.0) 350256.2 (9.3)56.8 (10.0)66.5/33.563.7/36.331.2 (4.5)31.4 (4.6)7.7 (5.5)8.2 (6.5)8.6 (1.1)8.5 (1.0)8.6 (0.1)^c^8.6 (0.1)^c^ 400160.3 (9.2)61.8 (8.5)54.9/45.151.3/48.728.7 (4.2)28.9 (3.9)10.2 (7.0)9.9 (6.0)8.9 (0.8)8.9 (0.8) 400254.7 (9.5)55.6 (8.9)55/4556.3/43.732.5 (4.6)32.2 (4.8)8.4 (5.6)9.0 (5.6)8.6 (0.9)8.6 (0.9) 401255.4 (8.4)56.3 (8.4)39.4/60.643.8/56.224.8 (3.0)25.1 (3.1)10.3 (6.2)10.0 (5.2)9.0 (0.9)9.1 (0.9) 401356.1 (9.9)57.1 (9.6)42.9/57.138.0/62.027.3 (3.7)27.2 (4.0)10.3 (6.4)10.8 (6.4)9.0 (1.0)9.2 (0.9) 401455.9 (10.5)55.3 (11.4)45.2/54.858/4234.6 (7.0)33.6 (6.3)8.5 (5.8)8.1 (5.1)8.8 (1.0)8.7 (1.0) 401654.9 (8.8)55.3 (8.5)54.2/45.853.6/46.434.5 (7.2)34.1 (7.2)10.7 (6.9)10.8 (6.7)8.4 (1.4)8.3 (1.4) 402052.5 (11.0)51.8 (10.3)48/5249.6/50.433.6 (7.0)33.6 (7.3)6.4 (4.9)5.8 (4.2)9.4 (1.2)^c^9.4 (1.3)^c^ 402154.2 (10.5)52.8 (9.8)47.8/52.245.5/54.533.4 (5.2)33.5 (6.2)10.1 (7.0)8.9 (6.6)9.1 (0.9)9.0 (0.9) 402253.6 (9.7)52.1 (10.3)47.5/52.548.5/51.534.5 (7.0)35.2 (7.4)7.5 (4.5)7.6 (6.0)9.0 (1.2)9.0 (1.2) 402760.9 (8.7)60.4 (9.1)61.0/39.057.0/43.029.5 (3.6)29.6 (3.6)9.9 (7.3)9.9 (6.4)8.9 (1.0)8.9 (0.9) 404060.0 (9.0)59.7 (9.0)52.5/47.658.7/41.429.2 (3.7)29.4 (3.5)9.0 (6.8)8.5 (6.1)8.7 (1.0)8.7 (1.0) 404260.6 (7.7)60.7 (8.1)55.3/44.750.0/50.030.1 (3.5)29.8 (3.4)10.0 (6.2)10.1 (6.9)7.6 (0.3)7.5 (0.4) 600156.1 (9.4)57.5 (8.5)62/3865/3531.3 (5.3)32.1 (5.4)8.6 (4.3)8.5 (4.8)9.1 (1.2)9.3 (1.1)Data are means (SD) unless otherwise indicated^a^SDs for trials 2002, 2003 and 2004 are unavailable in source documents^b^Data for trial number 3102 are unavailable^c^Adjusted mean (SEM)N/A, not applicable

Overall, there was no difference in the incidence of malignancies between insulin glargine-treated people and the comparator group (Table [3](#Tab3){ref-type="table"}), with 52 cases of malignant cancer documented as a serious treatment-emergent event in 45 people in the insulin glargine group (0.8%) and 48 cases in 46 people in the comparator group (0.9%). Among such malignancies, most occurred in people with type 2 diabetes, with 45 cases in 39 people in the insulin glargine group (1.0%) and 46 cases in 44 people in the comparator group (1.2%). Table 3All malignant neoplasms reported in controlled clinical trials comparing insulin glargine with a comparator (participants evaluable for safety)Trial durationInsulin glargineComparatorNo. of patientsAll malignanciesBreast cancerNo. of patientsAll malignanciesBreast cancerNo. affected (%) \[no. of events\]No. affected (%) \[no. of events\]No. affected (%) \[no. of events\]No. affected (%) \[no. of events\]Type 1 diabetes (12 trials): insulin glargine vs other basal insulin 30012922 (0.7) \[2\]029300 30042643 (1.1) \[3\]1 (0.4) \[1\]27000 30053101 (0.3) \[2\]03092 (0.6) \[2\]0 2002168008800 20032230011000 30031740017500 400329002700 400526002500 400653005200 401062006300 403085009000 403626002400 Total type 11,7126 (0.4) \[7\]1 (0.1) \[1\]1,5262 (0.1) \[2\]0Type 2 diabetes: insulin glargine vs NPH insulin ≤1 year in duration (ten trials)^a^ 30022893 (1.0) \[3\]02817 (2.5) \[7\]1 (0.4) \[1\] 30062596 (2.3) \[8\]02593 (1.2) \[4\]0 31021581 (0.6) \[1\]01591 (0.6) \[1\]0 40014643 (0.6) \[3\]02331 (0.4) \[1\]0 4002367003891 (0.3) \[1\]1 (0.3) \[1\] 2004136006800 40122210022300 40132310025000 40271770018700 600161004900 Total2,36313 (0.6) \[15\]02,09813 (0.6) \[14\]2 (0.1) \[2\]Type 2 diabetes: insulin glargine vs NPH insulin \>1 year in duration (one trial) 401651420 (3.9) \[23\]3 (0.6) \[3\]50331 (6.2) \[32\]4 (0.8)^b^Type 2 diabetes: insulin glargine vs oral agents (five trials) 35022031 (0.5) \[1\]019700 40141050011200 40201640018100 40221180013000 40421032 (1.9) \[2\]010800 Total6933 (0.4) \[3\]072800Type 2 diabetes: insulin glargine vs other insulin than NPH (three trials) 2006571 (1.8) \[1\]05700 4021113009900 40402052 (1.0) \[3\]021200 Total3753 (0.8) \[4\]036800 Total type 2 diabetes3,94539 (1.0) \[45\]3 (0.1) \[3\]3,69744 (1.2) \[46\]6 (0.2) \[6\] Grand total5,65745 (0.8) \[52\]4 (0.1) \[4\]5,22346 (0.9) \[48\]6 (0.1) \[6\]^a^One study used NPH premixed insulin (4027)^b^Includes one recurrent breast cancer; in addition, there was one case of breast cancer present at baseline that was not considered treatment emergent

The corresponding RR for malignant cancer with insulin glargine compared with the comparator is 0.90 (95% CI 0.60--1.36).

Four cases of malignant breast cancer were reported in the insulin glargine group (0.1%) and six cases in the control group (0.1%). The RR for breast cancer is 0.62 (95% CI 0.17--2.18).

These data were primarily driven by the findings in the 5 year RCT (study 4016) that compared insulin glargine (*n* = 514) with NPH insulin (*n* = 503) in people with type 2 diabetes who were randomised and received treatment \[[@CR7], [@CR8]\]. In that study, the overall number of people with neoplasms was similar in the insulin glargine and NPH insulin groups (57 \[11.1%\] and 62 \[12.3%\] people, respectively) \[[@CR8]\]. When considering only the number of people in the retinopathy study with malignant neoplasms reported as serious treatment-emergent events, the rate was also similar in both groups (insulin glargine vs NPH insulin, 23 cases in 20 people \[3.9%\] vs 32 cases in 31 people \[6.2%\]). Finally, the number of people with breast cancer reported as a serious adverse event in that study was similar between the two treatment groups (three \[0.6%\] vs four \[0.8%\] cases -- there was also an additional fifth case in the NPH insulin group, although this was reported as a non-serious adverse event).

Table [4](#Tab4){ref-type="table"} summarises the sites of all malignancies in the pooled studies comparing insulin glargine with comparator. The most frequently reported site (insulin glargine vs comparator) included the skin (16 events in 12 people \[0.2%\] vs seven events in six \[0.1%\] people, RR 1.85, 95% CI 0.69--4.92), colon and rectum (six \[0.1%\] vs ten \[0.2%\], RR 0.55, 95% CI 0.20--1.52), breast (four \[0.1%\] vs six \[0.1%\], RR 0.62, 95% CI 0.17--2.18) and gastrointestinal tract (six \[0.1%\] vs four \[0.1%\], RR 1.38; 95% CI 0.39--4.90). Table 4Location of malignancies in randomised controlled studies of insulin glargineClassificationNo. using insulin glargine (%) \[no. of events\]No. in the control group (%) \[no. of events\]Relative risk (95% CI)Total number of people5,657 (100) \[52\]5,223 (100) \[48\]--Blood2 (0.04) \[2\]1 (0.02) \[1\]1.85 ( 0.17--20.36)Vertebral body1 (0.02) \[1\]0--Breast4 (0.07) \[4\]6 (0.11) \[6\]0.62 (0.17--2.18)Nasal1 (0.02) \[1\]0--Lung3 (0.05) \[3\]3 (0.06) \[3\]0.92 (0.19--4.57)Gastrointestinal (not otherwise stated)6 (0.11) \[6\]4 (0.08) \[4\]1.38 (0.39--4.90)Colon and rectum6 (0.11) \[6\]10 (0.19) \[10\]0.55 (0.20--1.52)Hepatic and biliary2 (0.04) \[2\]3 (0.06) \[3\]0.62 (0.10--3.68)Pancreas3 (0.05) \[3\]3 (0.06) \[3\]^a^0.92 (0.19--4.57)Renal3 (0.05) \[3\]0--Prostate1 (0.02) \[1\]3 (0.06) \[3\]0.31 (0.03--2.96)Bladder02 (0.04) \[2\]--Genitourinary3 (0.05) \[3\]4 (0.08) \[4\]0.69 (0.16--3.09)Thyroid2 (0.04) \[2\]0--Endocrine01 (0.02) \[1\]--Neurological02 (0.04) \[2\]--Skin12 (0.21) \[16\]6 (0.11) \[7\]1.85 (0.69--4.92)Total number of people with malignancies^b^45 (0.80) \[52\]46 (0.88) \[48\]0.90 (0.60--1.36)^a^Includes one pancreatic carcinoma from study 3005 that was erroneously reported as a non-serious adverse event^b^The sum of each location of malignancies differs slightly from the total number owing to the fact that individuals could have malignancies in more than one location or more than one preferred term may be associated with a malignancy

With respect to the type of malignancy, at least two more tumours were reported in the comparator group vs the insulin glargine group for the following classifications: colon and rectum (ten \[0.2%\] vs six \[0.1%\]), prostate (three \[0.1%\] vs one \[0.0%\]), neurological (two \[0.0%\] vs zero \[0.0%\]) and bladder (two \[0.0%\] vs zero \[0.0%\]). Conversely, there were nine more cases of skin cancer in the insulin glargine group compared with the comparator group (16 cases in 12 people \[0.2%\] vs seven cases in six people \[0.1%\]), including an imbalance of six (0.1%) to one (0.0%) for malignant melanoma. However, in the 5 year Study 4016, the incidence of all melanomas (documented as serious and non-serious adverse events) was not different between treatment groups (three each, with one case in the comparator \[NPH insulin\] group and two in the insulin glargine group reported as serious adverse events).

Within the sanofi-aventis safety database, in addition to the RCTs, there are 26 completed uncontrolled studies with insulin glargine, involving a total of 68,201 participants with type 1 or type 2 diabetes treated for up to 3 years. The data from these 26 uncontrolled studies represent a total follow-up time of 22,074 person-years for insulin glargine treatment.

In total, there were 111 cases of malignancy, including nine cases of breast cancer, reported in these studies. The overall cancer rate is estimated to be 5.0 cases per 1,000 person-years (111 out of 22,074 person-years) and the breast cancer rate is estimated to be 82 cases per 100,000 person-years (that is, nine out of 11,027 person-years---the denominator here being the exposure of women in the type 2 diabetes RCTs). In investigator-sponsored trials and product registries (intensified monitoring) for which no enrolment figures are available, the sanofi-aventis safety database contains an additional 75 individuals with malignancies, including nine cases of breast cancer.

Discussion {#Sec4}
==========

Based on our analysis of 31 RCTs, insulin glargine was not associated with an increased incidence of cancer, including breast cancer, when compared with the control/comparator group.

The overall incidence of cancer in the trials included in this analysis was lower in people with type 1 diabetes than in those with type 2 diabetes, perhaps because the former were younger and less obese than the people with type 2 diabetes (Table [2](#Tab2){ref-type="table"}), and were exposed for a shorter time. Obesity increases the risk of colon cancer by as much as 1.5- to 2-fold and accounts for up to 35% of the total incidence of colon cancer \[[@CR9]\]. In terms of age, the prevalence of cancer increases with increasing age and peaks in people aged 75 years or older \[[@CR10], [@CR11]\]. People with type 2 diabetes in this analysis were typically in their mid to late fifties and, thus, the majority were at an age associated with greater risk for cancer compared with the people with type 1 diabetes.

The results presented are based on formal RCTs, which represent level 1---the highest level---of evidence-based study design. Another advantage of the present analysis is that the clinical trials database reviewed here included a large number of people (*n* = 10,880), allowing the opportunity to identify rarer adverse events. Furthermore, the events were recorded reasonably accurately, as in any RCT, as the monitoring of adverse events followed the rules of good clinical practice and international pharmacovigilance regulations \[[@CR12]\]. Finally, our analysis included one long-term 5 year controlled study that showed comparably reassuring findings, with no differences in the incidence of cancers between patients treated with insulin glargine and patients treated with NPH insulin.

Nevertheless, this analysis must be considered in light of some limitations. The duration of most of the studies was relatively short (mostly 6 months) and does not reflect the lifetime risk for cancer, while only one study was longer than 1 year. Nevertheless, if growth promotion is postulated as the mechanism of any increased cancer risk, it would appear early in the use of any therapeutic entity. None of the RCTs was specifically designed to evaluate the risk of cancer with insulin glargine, although all had mandatory reporting of adverse events, including treatment-emergent neoplasms. Randomised controlled trials may not fully reflect real-life clinical practice; investigators may, for example, be less likely to include people with previous malignancies. People using thiazolidinediones, which have been suggested as protective against breast or pancreatic cancer \[[@CR13], [@CR14]\] and linked with increases in bladder cancer, \[[@CR13]\] were often not included in the insulin studies, owing to the relative or absolute labelling restrictions in participating countries. Finally, the number of malignancies reported here may differ slightly from the published numbers for each study owing to differences in reporting methods; for example, only cases classified as serious treatment-emergent events were included in this analysis, whereas the original publications may have included cases classified as non-serious or serious. In addition, we only included treatment-emergent cases, whereas some of the publications may have included pre-existing cases.

However, analysis of the 26 uncontrolled trials with insulin glargine shows that the overall cancer rate is estimated to be 5.0 cases per 1,000 person-years. Compared with the age-adjusted incidence rate of 4.63 per 1,000 per year in the USA (based on cases diagnosed in 2002--2006 from 17 geographic areas included in the Surveillance, Epidemiology and End Results \[SEER\] programme), there was no indication of increased cancer risk in people with diabetes using insulin glargine. However, we acknowledge that under-reporting of cancer events can occur in uncontrolled observational studies, where follow-up with physicians is not always possible and, therefore, these results should be interpreted with caution.

For breast cancer, the incidence rate in women participating in non-interventional trials of insulin glargine may be estimated to be 82 cases per 100,000 person-years. Compared with the incidence rate of 124 per 100,000 women per year in the US SEER database, no safety signal for breast cancer was identified with the use of insulin glargine in these clinical trials.

In conclusion, these data suggest that insulin glargine is not associated with an increased risk of cancer compared with the different comparators (mainly NPH insulin). While the data provide useful reassuring and contributory information regarding the safety of insulin glargine, they underscore the importance of continued long-term follow up of participants in clinical trials.
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